Lupin gets USFDA Nod for Generic Flucytosine Cap | CORPORATE ETHOS

Lupin gets USFDA Nod for Generic Flucytosine Cap

By: | January 5, 2018
lupin

Jan 5: Pharma major Lupin Ltd on Friday announced that the launch of its Flucytosine capsules USP, 250 mg and 500 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier.

“Novel’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceutical’s International Inc’s ANCOBON Capsules, 250 mg and 500 mg. Flucytosine Capsules USP, 250 mg and 500 mg are indicated for the treatment of serious infections caused by susceptible strains of Candida and Cyptococcus,” Lupin said in a BSE filing.

Flucytosine Capsules USP, 250 mg and 500 mg had annual sales of approximately $48 million in the US, according to IMS MAT October 2017 data.

Lupin shares were trading at Rs 898.60, up 2.40% from the previous closing of Rs 877.50, on BSE at 2.56 pm today.